ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. (ZNTL) has 9 SEC Form 4 filings (13 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jun 18, 2026.
The most active filer is PAO and PFO Vultaggio Vincent with 3 filings. Insiders have net sold $127K over the trailing 6 months.
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$127K
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$300.4M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Vultaggio VincentFirst filing | PAO and PFO | Sale | 29,951 | $73K | Feb 10 | SEC ↗ |
Vultaggio VincentFirst filing | PAO and PFO | Sale | 3,379 | $8K | Feb 10 | SEC ↗ |
Vultaggio VincentFirst filing | PAO and PFO | Sale | 6,894 | $17K | Feb 10 | SEC ↗ |
EASTLAND JULIA MARIEFirst filing | CEO & President | Sale | 7,866 | $19K | Feb 10 | SEC ↗ |
EASTLAND JULIA MARIEFirst filing | CEO & President | Sale | 889 | $2K | Feb 10 | SEC ↗ |
Bruns IngmarFirst filing | Chief Medical Officer | Sale | 2,962 | $7K | Feb 10 | SEC ↗ |
Bruns IngmarFirst filing | Chief Medical Officer | Sale | 335 | $802 | Feb 10 | SEC ↗ |
Related companies
Zentalis Pharmaceuticals, Inc. is in the Healthcare sector.